Rubinstein-Taybi Syndrome: Epigenetics, animals models, therapeutic trials

– Epigenetics implication of CREBBP and EP300 during normal and abnormal differentiation of cortical and hippocampal neurons
– New therapeutic targets identification
– Histone deacetylase inhibitors trials in CBP mouse model
– Development of phosphodiesterase 4D (PDE4-D) inhibitors, regarding new clinical trials

IMG_0821-web

Contributing Members

D. Lacombe
P. Fergelot
B. Arveiler
J. Van-Gils

National and International Collaborations

Pr. Raoul Hennekam. [Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands]
Dr. Valérie Lallemand-Mezger. [Epigenetics and Cell Fate, UMR7216, University Paris Diderot, 75013 PARIS]
Dr. Angel Barco. [Instituto de Neurociencias (UMH-CSIC), Alicante, Spain]
Dr. Aline Marighetto. [Physiopathologie de la mémoire déclarative, INSERM U1215, Neurocentre Magendie, Bordeaux]
Pr. Luc Grislain. [Dept. Pharmacologie, Université de Bordeaux]
Pr. Nicolas Levy. [Université de Marseille]
Dr. Frédérique Magdinier. [Université de Marseille]
Pr. David Geneviève. [Service Génétique, Université de Montpellier]